Web-Base App To Improve Aromatase Inhibitor Adherence (AETAPP)
Breast Neoplasm Female
About this trial
This is an interventional supportive care trial for Breast Neoplasm Female
Eligibility Criteria
Inclusion Criteria:
- Adult female patients (age≥18)
- Diagnosed with early stage (I-III) HR+ breast cancer
- New prescription for an aromatase inhibitor
- Have a mobile device with a data plan or a home computer with Internet
- Have a valid email address
- Willing to complete brief weekly symptom reports on the app
Exclusion Criteria:
- Unable to communicate in English
- Patients with prior use of adjuvant endocrine therapy will also be excluded
- Patients concurrently undergoing surgery, chemotherapy or radiation will also be excluded
- Current diagnosis of rheumatoid arthritis
- Chronic daily narcotic usage
Sites / Locations
- West Cancer Center, MIDTOWN, 1588 Union Ave.
- West Cancer Center, EAST MEMPHIS, 7945 Wolf River Blvd
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
App
Usual Care
The web-based app will be used to ask participants about their aromatase inhibitor use in the previous 7 days and ask about treatment-related adverse symptoms, or changes in the severity of symptoms. Participants will receive reminders via text or email to use the app once per week. All participants will be followed for a 6-8 weeks (depending on the data of participants' in-clinic follow-up visit) and will be asked to complete a baseline survey at enrollment and a follow-up survey at their 6-8 week in-clinic follow-up visit.
Participants will have access to the web-based app, but will not receive reminders. All participants will be followed for a 6-8 weeks (depending on the data of participants' in-clinic follow-up visit) and will be asked to complete a baseline survey at enrollment and a follow-up survey at their 6-8 week in-clinic follow-up visit.